Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. An independent data monitoring committee is recommending stopping enrollment of a phase 3 trial of a monoclonal antibody for COVID-19 because interim results indicate an 85% (P = . 002) reduction in hospitalizations or death, two companies have announced
Visit the link to check the full article right here.